Founded
Address
MVM Life Science Partners LLP
6 Henrietta Street
London
WC2E 8PU
United Kingdom
Phone
Website
Recent investment activity
KANDO id: 27801
Corporate information
Official name
MVM Life Science Partners Limited Liability Partnership
Registration country
Company type
Venture capital firm which invests in technologies and products for the life science and healthcare marketsOverview
MVM has been investing in high growth healthcare businesses since 1997. We have a broad, global, investment remit including medical technology, pharmaceuticals, biotechnology, diagnostics, life science tools, and digital health, supported by our investment teams in Boston and London.
Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 1 - 21 of 21| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Alliance Pharma PLC | N/A | ||||
|
|
Biomedix Inc | N/A | ||||
|
|
Cara Therapeutics Inc | N/A | ||||
|
|
Cheetah Medical Holdings Inc | N/A | ||||
|
|
Health Information Ltd | N/A | ||||
|
|
Heptares Therapeutics Ltd | Series A | ||||
|
|
Heptares Therapeutics Ltd | Seed | ||||
|
|
Lombard Medical Technologies PLC | N/A | ||||
|
|
Momenta Pharmaceuticals Inc | Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. | N/A | |||
|
|
Pulmagen Therapeutics Ltd | CRTH2 antagonists for the treatment of severe asthma and COPD. Signed a subcontracting agreement with Argenta. | N/A | |||
|
|
SOLX Inc | N/A | ||||
|
|
Udcast | N/A | ||||
|
|
Vantia Ltd | N/A | ||||
|
|
Vascular Pathways Inc | N/A | ||||
|
|
Xention Ltd | N/A | ||||
|
|
AccuVein Inc | N/A | ||||
|
|
Aegerion Pharmaceuticals Inc | N/A | ||||
|
|
Biovex Inc (Biovex Group Inc) | Biotechnology company developing new generation biologics for the treatment of cancer and infectious disease. | N/A | |||
|
Horizon Discovery Ltd | Series C Hugo Harrod | ||||
|
|
Horizon Discovery Ltd | Series C led the round Hugo Harrod | ||||
|
|
Tarsa Therapeutics Inc | Developer of an oral formulation of calcitonin for the treatment of osteoporosis | N/A |
Former team members
| Employee | Company | Position | ||
|---|---|---|---|---|
| Martin Murphy | Syncona Investment Management Ltd | |||
| Martin Murphy | Quell Therapeutics Ltd |